Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

Key Takeaways

• MG involves antibodies targeting acetylcholine receptors, disrupting neuromuscular transmission and causing muscle weakness.
• New therapeutic targets include MuSK and LRP4, offering potential for novel treatment strategies.
• Standard gMG treatment includes acetylcholinesterase inhibitors, corticosteroids, and immunosuppressants.
• Emerging therapies focus on monoclonal antibodies and complement inhibitors for targeted disease management.